Want to see BAX full AI Analyst Report?
Operating Income by Segment
Reveals profitability across different business units, highlighting which segments are driving earnings and where there might be challenges or opportunities for growth.Baxter’s segment profits cratered into early‑2026—Pharma and HST show sharp year‑over‑year erosion while MPT, historically the largest contributor, has weakened versus prior peaks—reflecting supply disruptions (injectables), Novum shipment/return risk, tariff and absorption pressures. Management’s call confirms these drivers and pins recovery to a stronger second half via volume, cost actions and inventory roll‑through; near‑term earnings remain exposed to unresolved Novum and contract‑manufacturer supply issues, so upside depends on remediation and HST timing.
Date | Other | Medical Products and Therapies | Healthcare Systems and Technologies | Pharmaceuticals |
|---|---|---|---|---|
Jun 30, 2026 | $6.00M | $400.00M | $163.00M | $0.00 |
Mar 31, 2026 | $11.00M | $186.00M | $66.00M | $46.00M |
Dec 31, 2025 | $23.00M | $214.00M | $126.00M | $39.00M |
Sep 30, 2025 | $5.00M | $273.00M | $104.00M | $56.00M |
Jun 30, 2025 | $6.00M | $239.00M | $118.00M | $64.00M |
Mar 31, 2025 | $9.00M | $244.00M | $93.00M | $63.00M |
Dec 31, 2024 | $3.00M | $217.00M | $145.00M | $102.00M |
Sep 30, 2024 | $2.00M | $268.00M | $136.00M | $58.00M |
Jun 30, 2024 | $9.00M | $238.00M | $120.00M | $75.00M |
Mar 31, 2024 | $4.00M | $227.00M | $67.00M | $78.00M |